| http://www.w3.org/ns/prov#value | - RSV is a viral pathogen that produces ann...MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV SAN FRANCISCO, October 29, 2007 MedImmune today announced results from a recent economic analysis of Synagis (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncy
|
